Head and Neck Squamous Cell Carcinoma (HNSCC) Clinical Trial
Official title:
Efficacy and Safety of Netupitant and Palonosetron Hydrochloride Capsules in Preventing Nausea and Vomiting Induced by Radiochemotherapy in Head and Neck Squamous Cell Carcinoma
The enrolled head and neck squamous cell carcinoma patients in this study received high-dose multiday chemotherapy with cisplatin and synchronous radiation therapy, which had a high risk of nausea and vomiting. On the first and third days, they took Netopitam Palonosetron capsules and dexamethasone to reduce the incidence of acute vomiting. The aim of this study is to evaluate the antiemetic effect of Netopitam Palonosetron capsules and to explore the effectiveness of using Netopitam Palonosetron capsules again for antiemetic treatment during the study period when breakthrough vomiting occurs.
Status | Not yet recruiting |
Enrollment | 36 |
Est. completion date | January 1, 2026 |
Est. primary completion date | January 1, 2026 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: 1. Male or female, aged 18-75 years old; 2. Head and neck tumors confirmed by histology or cytology (including oral cancer, oropharyngeal cancer, hypopharyngeal cancer, and laryngeal cancer); 3. Receive radical synchronous radiotherapy and chemotherapy; 4. The Eastern Oncology Collaborative Group (ECOG) physical fitness score of the subjects was = 2 points; 5. Adequate organ and bone marrow function; 6. The expected life is at least 12 weeks; 7. Pregnant or fertile patients (male or female) use reliable contraceptive measures; 8. When screening female patients with potential pregnancy, the pregnancy test must be negative; 9. The subjects voluntarily and strictly comply with the requirements of the research protocol and sign a written informed consent form. Exclusion Criteria: 1. Recurrent and metastatic head and neck tumors; 2. Previously underwent tumor resection surgery for treatment; 3. Patients with platinum drug intolerance; 4. Receiving any known or potential antiemetic medication within 24 hours prior to the first day, or experiencing symptoms of vomiting, retching, or mild nausea within 24 hours prior to the first day; 5. Take NK1(neurokinin-1) receptor antagonists or any study medication within 4 weeks before the start of the experiment; 6. Use CYP3A4 inducer within 4 weeks before chemotherapy, and use CYP3A4 substrate or strong or moderate CYP3A4 inhibitor within 1 week; 7. Serious cardiovascular, pulmonary, diabetes, mental and other diseases; 8. Pregnant or lactating women, patients with fertility who are unwilling or unable to take effective contraceptive measures; 9. Drug and/or alcohol abuse; 10. Hypocalcemia or any other condition that may cause vomiting; 11. There are significant factors that affect the absorption of oral medication, such as chronic diarrhea and intestinal obstruction; 12. The subject has allergic reactions to Netopitam Palonosetron capsules or any of their excipients; 13. Within 30 days prior to the baseline visit, the subject participated in another clinical study and used any exploratory drugs or devices; Allow participation in observational research; 14. The researcher determines other situations that may affect the progress of clinical research and the determination of research results. |
Country | Name | City | State |
---|---|---|---|
China | Sichuan Cancer Hospital and Research Institute | Chengdu | Sichuan |
Lead Sponsor | Collaborator |
---|---|
Sichuan Cancer Hospital and Research Institute |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The complete response rate during synchronous radiotherapy and chemotherapy (defined as no vomiting episodes and no emergency medication). | 1 month | ||
Secondary | No significant nausea rate during synchronous radiotherapy and chemotherapy | 1 month | ||
Secondary | Nausea free rate during synchronous radiotherapy and chemotherapy | 1 month | ||
Secondary | No vomiting rate during synchronous radiotherapy and chemotherapy | 1 month | ||
Secondary | The rate of non emergency medication during synchronous radiotherapy and chemotherapy | 1 month | ||
Secondary | The prevalence and severity of oral/oropharyngeal mucositis during synchronous radiotherapy and chemotherapy | 1 month | ||
Secondary | Successful rescue rate of breakthrough vomiting: (defined as no vomiting within 48 hours) | 1 month | ||
Secondary | Evaluate the impact of medication on patients' daily activities of life (evaluated based on the nausea and vomiting questionnaire FLIE) | 1 month |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT02211027 -
Biological Vaccine: Semi-allogeneic Human Fibroblasts (MRC-5) Transfected With DNA
|
Phase 1 | |
Recruiting |
NCT04083599 -
GEN1042 Safety Trial and Anti-tumor Activity in Subjects With Malignant Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03735628 -
An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05891171 -
Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers
|
Phase 1 | |
Recruiting |
NCT03546582 -
SBRT +/- Pembrolizumab in Patients With Local-Regionally Recurrent or Second Primary Head and Neck Carcinoma
|
Phase 2 | |
Terminated |
NCT00911326 -
Evaluation of Sentinel Lymph Nodes in Head and Neck Squamous Cell Carcinoma
|
Phase 3 | |
Recruiting |
NCT06295731 -
INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC
|
Phase 2/Phase 3 | |
Completed |
NCT04220866 -
Study of Intratumoral (IT) Ulevostinag (MK-1454) in Combination With Intravenous (IV) Pembrolizumab (MK-3475) Compared to IV Pembrolizumab Alone as the First Line Treatment of Metastatic or Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) (MK-1454-002)
|
Phase 2 | |
Withdrawn |
NCT03114280 -
Pembrolizumab and Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma (PICH Study)
|
Phase 1/Phase 2 | |
Completed |
NCT02764593 -
Safety Testing of Adding Nivolumab to Chemotherapy in Patients With Intermediate and High-Risk Local-Regionally Advanced Head and Neck Cancer
|
Phase 1 | |
Withdrawn |
NCT04849377 -
RBD-HPV: Risk-Based De-Intensification for HPV+ HNSCC
|
Phase 2 | |
Completed |
NCT03268993 -
Effects of Avmacol® in the Oral Mucosa of Patients Following Curative Treatment for Tobacco-related Head and Neck Cancer
|
N/A | |
Recruiting |
NCT04284540 -
Hypofractionated Radiotherapy in Elderly Patients With Head & Neck Squamous Cell Carcinoma
|
N/A | |
Recruiting |
NCT04080804 -
Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer
|
Phase 2 | |
Active, not recruiting |
NCT04215978 -
Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT03746431 -
A Phase 1/2 Study of [225Ac]-FPI-1434 Injection
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT05249426 -
A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver Cancer
|
Phase 1 | |
Not yet recruiting |
NCT05473156 -
A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients With Locally Advanced or Metastatic Solid Tumors, and Expansion to Selected Malignancies
|
Phase 1/Phase 2 | |
Completed |
NCT02684253 -
Screening Trial of Nivolumab With Image Guided, Stereotactic Body Radiotherapy (SBRT) Versus Nivolumab Alone in Patients With Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
|
Phase 2 | |
Terminated |
NCT03276819 -
A Clinical and Biological Umbrella Protocol for Smoker or Non-smoker Patients With OPML or HNSCC
|
N/A |